Supply of IMMUCYST BCG 6.6 - 19.2 x 100000000 CFU powder for injection vial by Sanofi-Aventis Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply, advertising, and importation of therapeutic goods in Australia, ensuring that these goods meet safety, quality, and efficacy standards. This Act was introduced to address the need for comprehensive regulation of therapeutic goods to protect public health and safety. The Act is administered by the Australian Parliament and its primary policy objective is to safeguard the health and safety of the Australian population by regulating the therapeutic goods market effectively. The Act empowers the Therapeutic Goods Administration (TGA) to control the quality, efficacy, and safety of therapeutic goods through various mechanisms, including the issuance of licences, permits, and approvals. In this context, the Act enables the Secretary of the Department of Health and Ageing to grant specific exemptions under certain conditions, ensuring that the therapeutic goods supplied in Australia meet the necessary regulatory standards while allowing for some flexibility in particular cases.

Scope and Application

The Therapeutic Goods Act 1989, as amended, applies to the regulation of therapeutic goods in Australia, encompassing a wide range of products including medicines, medical devices, blood, and tissues. This legislation applies to entities such as manufacturers, importers, and suppliers of therapeutic goods, imposing obligations and requirements on them to ensure the safety, quality, and efficacy of these goods. The Act extends to the entire Commonwealth of Australia, setting national standards for the approval, manufacturing, and distribution of therapeutic goods. Notably, the Act provides for specific exemptions and exceptions, particularly under sections 14 and 14A, which allow for the supply of certain therapeutic goods that do not fully comply with standard regulations, provided certain conditions are met. These conditions often include specific labelling requirements and the provision of additional information to healthcare professionals. The Act also allows for the application of subordinate instruments to further extend or restrict its application, ensuring that the regulation of therapeutic goods remains dynamic and responsive to emerging needs and technologies.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 allow the delegate of the Secretary to consent to certain activities that would otherwise be non-compliant with the Act or other regulations. In this particular case, the delegate has consented to the supply of a specific medical product, IMMUCYST BCG 6.6 – 19.2 x 100000000 CFU powder for injection vial, by Sanofi-Aventis Australia Pty Ltd, under certain conditions. This consent acknowledges that the product will be supplied with US packaging under the trade name THERACYS (BCG), and that it will not comply with Therapeutic Goods Order No 69, which outlines the general requirements for labels for medicines, nor will it meet the sterility test specified in the default Standard (section 14(a), (b) and (c)). The obligations imposed by this Act on the parties involved include the submission of specific labels for the product. These labels must be those submitted with the application, specifically the US carton and vial labels, but with an over-sticker containing the Australian Register of Therapeutic Goods (ARTG) number and the local sponsor's name and address on the carton label (section 15(1)(1)). Furthermore, each pack of the product must be supplied with Australian product information (PI) and a "Dear Healthcare Professional" letter, the draft of which was provided to the Therapeutic Goods Administration (TGA) on 25 October 2012 (section 15(1)(2)). The exemption provided by this consent applies to each lot of TheraCys that is specifically reviewed by the TGA and subject to the normal Lot Release process (section 15(1)(3)). Failure to comply with the conditions outlined in this consent may result in legal consequences. While the Act does not specify particular offences or penalties for non-compliance with this consent, general provisions in the Therapeutic Goods Act 1989 may apply. For example, supplying therapeutic goods that do not meet the required standards could potentially be considered an offence under section 26, which carries a maximum penalty of five years imprisonment or a fine of up to $330,000 for individuals, and up to $1.65 million for corporations. Additionally, the TGA may take enforcement action, such as product recalls, seizure of non-compliant goods, or the imposition of administrative penalties. It is important for all parties involved to adhere to the conditions of this consent to avoid any potential legal ramifications.